Last reviewed · How we verify
NCT04441840
Immune and Recovery Modulating Impact of Probiotic Supplementation After Intense Resistance Exercise
NA trial testing Active Probiotic Culture in Immune Markers in 75 participants. Completed in 1 August 2021.
1 August 2021
Quick facts
| Lead sponsor | Lindenwood University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 75 |
| Start date | 16 April 2019 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Active Probiotic Culture
- Inactive Probiotic Culture
Conditions studied
- Immune Markers — all drugs for Immune Markers →
- Complete Blood Count (CBC) With Platelet Differentials — all drugs for Complete Blood Count (CBC) With Platelet Differentials →
- Muscle Damage — all drugs for Muscle Damage →
- Muscular Force Production — all drugs for Muscular Force Production →
Sponsor
Lindenwood University
Who can join
Adults 18 to 55, male only, with Immune Markers or Complete Blood Count (CBC) With Platelet Differentials. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study proposal seeks to examine the efficacy of probiotic supplementation at mitigating changes in immune function and recovery after completion of intense, stressful exercise while also allowing for a better understanding of its ability to promote recovery and maintenance of physical performance.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04441840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Lindenwood University trials
Trials by the same sponsor.
- NCT07387991 — Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms · NA · not yet recruiting
- NCT07388264 — Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes · NA · recruiting
- NCT07310108 — Evaluation of Cordyceps Militaris M2-116-04 for Its Potential Sport and Exercise Nutrition Applications in Healthy Activ · NA · completed
- NCT06672952 — Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Othe · NA · recruiting
- NCT07502924 — Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04441840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lindenwood University
- Last refreshed: 5 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing